EZH2 and mesenchymal cell neoplasm: EZH2 inhibitors demethylate immune-response and antigen presentation promoter regions, restoring major histocompatibility complex-I expression which could be used as a strategy to sensitize mesenchymal tumors to chemotherapy and immunotherapy [58].